← All organizations

Human Genome Sciences

For profitContributed to NME

Also known as: Human Genome Sciences Inc. | HUMAN GENOME SCIENCES INC. | Human Genome Sciences Inc., a GSK Company

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Mar 20, 2013

Acquired by GlaxoSmithKline on Jan 1, 2012

Timeline

1990s

Jan 1, 1992
Human Genome Sciences— Founded

2010s

Jan 1, 2012
GlaxoSmithKline— Acquired By
Dec 14, 2012
raxibacumab— Marketing Organization
Dec 14, 2012
raxibacumab— NDA Organization

Drugs by trial phase (18 distinct, 46 trials)

Phase 4 (2 own, 0 via acquisition)

Phase 3 (4 own, 0 via acquisition)

Phase 2 (6 own, 0 via acquisition)

Phase 1 (6 own, 0 via acquisition)

Marketed drugs (2)

Recent trials (50)

NCT01663623Lead sponsorPhase 3Mar 20, 2013
NCT01632241Lead sponsorPhase 4Feb 19, 2013
NCT01649765CollaboratorPhase 2Sep 1, 2012
NCT01670565CollaboratorPhase 2Aug 1, 2012
NCT01639339Lead sponsorPhase 3Jul 1, 2012
NCT01705977Lead sponsorPhase 4Jul 1, 2012
NCT01597622CollaboratorPhase 3Jun 1, 2012
NCT01604863Lead sponsorPhase 1Jun 1, 2012
NCT01597492Lead sponsorPhase 4May 1, 2012
NCT01434576Lead sponsorPhase 1Dec 1, 2011
NCT01484496Lead sponsorPhase 3Nov 1, 2011
NCT01345253CollaboratorPhase 3May 23, 2011
NCT01583530Lead sponsorPhase 1Feb 1, 2011
NCT01258608Lead sponsorPhase 2Feb 1, 2011
NCT01088347CollaboratorPhase 1/Phase 2Mar 1, 2010

Details

Founded: Rockville, MD, US Jan 1, 1992
First NDA: Mar 10, 2011
Last known activity: Mar 20, 2013

Designations held

Orphan drug
Fast track

Notes

Acquired by GlaxoSmithKline